Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.

ABSTRACT:

Importance

Since 2011, immune checkpoint inhibitors (ICIs) have been effective treatment options for advanced melanoma. Little is known about how risks of immune-related adverse events (irAEs) vary by ICIs.

Objective

To compare the risk of irAEs across different treatment regimens for advanced melanoma using network meta-analysis.

Data sources

PubMed/MEDLINE, Embase, Web of Science, and Scopus were searched for all randomized clinical trial (RCT) articles published from January 1, 2010, through June 30, 2019.

Study selection

Studies included phases 2 and 3 RCTs in the treatment of advanced melanoma that compared ICIs (ipilimumab, nivolumab, and pembrolizumab) with chemotherapy drugs (eg, dacarbazine, carboplatin, and paclitaxel) or different ICI regimens.

Da

SUBMITTER: Chang CY 

PROVIDER: S-EPMC7097702 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature